| Name | Title | Contact Details |
|---|
Our privacy-enhancing solutions extract maximum value from your data while stimulating growth, mitigating privacy risks, and enhancing brand reputation.
WealthKernel provides everything you need to power your digital wealth offering. Onboarding, dealing, custody, regulatory, and tech solutions in one platform.
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Catapult exists to unleash the potential of every athlete and team on earth. Operating at the intersection of sports science and analytics, Catapult products are designed to optimize performance, avoid injury, and quantify return to play. Catapult has over 400 staff based across 24 locations worldwide, working with more than 3,200 elite teams in 137 countries globally. To learn more about Catapult and to inquire about accessing performance analytics for a team or athlete, visit us at catapultsports.com. Catapult Group International Limited (CAT) is listed on the Australian Stock Exchange.
Drive more In-Person and Virtual Meetings before, during, and after Events, Webinars, and Digital Campaigns using our virtual meeting software. Learn How.